Active — Not RecruitingNot Applicable

Edwards EVOQUE Eos MISCEND Study

United States123 participantsStarted 2015-02-06

Plain-language summary

Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinically significant, symptomatic mitral regurgitation * High risk for open-heart surgery * Meets anatomical criteria Exclusion Criteria: * Unsuitable anatomy * Patient is inoperable

What they're measuring

Composite of major adverse events

Timeframe: 30 days

Trial details

NCT IDNCT02718001

SponsorEdwards Lifesciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-04-30

View on ClinicalTrials.gov More Mitral Valve Regurgitation (Degenerative or Functional) trials